| Outcome |
Relative effect
(95% CI) |
Absolute effect
(95% CI)1 |
Certainty of the Evidence
(GRADE) |
Clinical improvement
D28 |
RR: 1.05
(0.96 - 1.14) |
42 more per 1000
(from 33 fewer to 116 more)
|
Moderate certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Serious
due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
| 2 trials
Caricchio R, 2021; Cremer P, 2021
499 participants
|
|
Canakinumab
873 per 1,000
(798 - 948) |
Placebo
831
per 1,000 |
|
Clinical improvement
D60 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above)
D28 |
RR: 0.72
(0.44 - 1.20) |
35 fewer per 1000
(from 69 fewer to 25 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 2 trials
Caricchio R, 2021; Cremer P, 2021
499 participants
|
|
Canakinumab
89 per 1,000
(54 - 148) |
Placebo
123
per 1,000 |
|
WHO progression score (level 7 or above)
D60 |
Outcome not yet measured or reported
|
|
All-cause mortality
D28 |
RR: 0.75
(0.39 - 1.42) |
20 fewer per 1000
(from 48 fewer to 33 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 2 trials
Caricchio R, 2021; Cremer P, 2021
499 participants
|
|
Canakinumab
59 per 1,000
(30 - 111) |
Placebo
78
per 1,000 |
|
All-cause mortality
D60 |
RR: 0.79
(0.48 - 1.30) |
26 fewer per 1000
(from 64 fewer to 37 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 2 trials
Cremer P, 2021; Caricchio R, 2021
499 participants
|
|
Canakinumab
98 per 1,000
(59 - 160) |
Placebo
123
per 1,000 |
|
Viral negative conversion
D7 |
Outcome not yet measured or reported
|
|
Adverse events
|
RR: 1.02
(0.86 - 1.21) |
11 more per 1000
(from 74 fewer to 111 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious
We presume that the adverse event rates and the corresponding relative risks, are similar across diverse settings, therefore not downgraded for indirectness Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 1 trials
Caricchio R, 2021
454 participants
|
|
Canakinumab
539 per 1,000
(455 - 640) |
Placebo
529
per 1,000 |
|
Serious adverse events
|
RR: 0.88
(0.65 - 1.21) |
30 fewer per 1000
(from 86 fewer to 52 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 2 trials
Caricchio R, 2021; Cremer P, 2021
499 participants
|
|
Canakinumab
217 per 1,000
(160 - 299) |
Placebo
247
per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
